Delcath Systems DCTH Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenue by Product | ||||||
| CHEMOSAT | $6.38M-0.2% | $6.4M+4.2% | $6.14M+2.5% | $5.99M+8.3% | $5.53M+12.9% | |
| HEPZATO KIT | $84.06M+6.6% | $78.84M+7.3% | $73.46M+14.3% | $64.25M+33.0% | $48.32M+49.6% | |
| Number of orphan drug designations granted by FDA by Product | ||||||
| HEPZATO KIT, Doxorubicin | 40.0% | 40.0% | 40.0% | 4— | —— | |
| HEPZATO KIT, Melphalan | 200.0% | 200.0% | 200.0% | 20— | —— | |
| HEPZATO KIT | 240.0% | 240.0% | 240.0% | 24— | —— | |
| Operating Lease, Payments by Geography | ||||||
| Ireland | $46K0.0% | $46K+31.4% | $35K-20.5% | $44K-2.2% | $45K+4.7% | |
| U.S. | $144K0.0% | $144K-5.3% | $152K0.0% | $152K0.0% | $152K+26.7% | |
| Lessee, Operating Lease, Liability, to be Paid by Geography | ||||||
| Ireland | $132K-24.6% | $175K-17.8% | $213K-16.8% | $256K-12.9% | $294K-12.5% | |
| U.S. | $5.05M-2.8% | $5.19M-2.7% | $5.34M-2.6% | $5.48M-2.6% | $5.63M-2.5% | |
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount by Geography | ||||||
| Ireland | $4K-42.9% | $7K-30.0% | $10K-28.6% | $14K-26.3% | $19K-20.8% | |
| U.S. | $1.38M-5.1% | $1.45M-5.0% | $1.53M-4.9% | $1.61M-4.7% | $1.68M-4.5% | |
| Weighted average discount rate - operating leases by Geography | ||||||
| Ireland | 32%0.0pp | 32%0.0pp | 32%0.0pp | 32%0.0pp | 32%0.0pp | |
| U.S. | 32%0.0pp | 32%0.0pp | 32%0.0pp | 32%0.0pp | 32%0.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Delcath Systems break its business down?
- Delcath Systems (DCTH) reports product revenue by product across 2 parts — CHEMOSAT and HEPZATO KIT. Each is extracted from the segment footnotes and tracked over time.
- Where does Delcath Systems's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Delcath Systems's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
